Research progress of HGF/c-MET signaling pathway inhibitors in antipancreatic cancer

doi:10.3760/cma.j.issn.1673-422X.2017.04.017

Abstract

Abstract: Pancreatic cancer is one of the most malignant tumors. Targeted therapy has become an important part of the treatment of pancreatic cancer. The signaling pathways such as hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway, inhibition of which may exerts an antitumor effect, play extremely important roles in the occurrence and development of pancreatic cancer. Therefore, the research of HGF/c-MET targeted inhibitors opens up a new avenue for treatment of pancreatic cancer.

Key words: Hepatocyte growth factor, Pancreatic neoplasms, Proto-oncogene proteins c-met

Qiao Yinbiao, Yang Bo. Research progress of HGF/c-MET signaling pathway inhibitors in antipancreatic cancer[J]. Journal of International Oncology, 2017, 44(4): 304-306.

References

［1］ Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and Met signaling［J］. Int J Cancer, 2014, 135(5): 1110-1118. DOI: 10.1002/ijc.28765. ［2］ Pothula SP, Xu ZH, Goldstein D, et al. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer［J］. Br J Cancer, 2016, 114(3): 269-280. DOI: 10.1038/bjc.2015.478. ［3］ Delitto D, Vertes-George E, Hughes SJ, et al. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer［J］. World J Gastroenterol, 2014, 20(26): 8458-8470. DOI: 10.3748/wjg.v20.i26.8458. ［4］ Huang C, Qiu ZJ, Wang LW, et al. A novel FoxM1-Caveolin signaling pathway promotes pancreatic cancer invasion and metastasis［J］. Cancer Res, 2012, 72(3): 655-665. DOI: 10.1158/0008-5472.CAN-11-3102. ［5］ Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells［J］. J Cell Biochem, 2011, 112(9): 2296-2306. DOI: 10.1002/jcb.23150. ［6］ Cui J, Xia T, Xie D, et al. HGF/c-Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes［J］. Oncogene, 2016, 35(36): 4708-4718. DOI: 10.1038/onc.2016.14. ［7］ Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions［J］. Nat Rev Cancer, 2014, 14(11): 736-746. DOI: 10.1038/nrc3818. ［8］ Patel MB, Pothula SP, Xu Z, et al. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer［J］. Carcinogenesis, 2014, 35(8): 1891-1900. DOI: 10.1093/carcin/bgu122. ［9］ Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting Met in cancer: rationale and progress［J］. Nat Rev Cancer, 2012, 12(2): 89-103. DOI: 10.1038/nrc3205. ［10］ Garajova I, Giovannetti E, Biasco G, et al. c-Met as a target for personalized therapy［J］. Transl Oncogenomics, 2015, 7(Suppl 1): 13-31. DOI: 10.4137/TOG.S30534. ［11］ Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling［J］. Oncotarget, 2015, 6(17): 14940-14952. DOI: 10.18632/oncotarget.3613. ［12］ Grullich C. Cabozantinib: a Met, RET, and VEGFR2 tyrosine kinase inhibitor［J］. Recent Results Cancer Res, 2014, 201: 207-214. DOI: 10.1007/978-3-642-54490-3_12. ［13］ Hage C, Rausch V, Giese N, et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer［J］. Cell Death Dis, 2013, 4(5): e627-e627. DOI: 10.1038/cddis.2013.158. ［14］ Zhen DB, Griffith KA, Ruch JM, et al. A phase Ⅰ trial of cabozantinib and gemcitabine in advanced pancreatic cancer［J］. Invest New Drugs, 2016, 34(6): 733-739. DOI: 10.1007/s10637-016-0376-1. ［15］ You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer［J］. Cancer Res, 2011, 71(14): 4758-4768. DOI: 10.1158/0008-5472.CAN-10-2527. ［16］ Liu XD, Wang Q, Yang GJ, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-Dependent signaling, neoplastic activities, and Cross-Talk with EGFR and HER3［J］. Clin Cancer Res, 2011, 17(22): 7127-7138. DOI: 10.1158/1078-0432.CCR-11-1157. ［17］ Brandes F, Schmidt K, Wagner C, et al. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model［J］. BMC Cancer, 2015, 15: 71. DOI: 10.1186/s12885-015-1064-9.

[1]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[2]	Yan Zhiying, Mao Yifeng, Zhu Yingwei, Xu Kequn. Role of heterogeneity of cancer-associated fibroblasts in targeted therapy of pancreatic cancer [J]. Journal of International Oncology, 2021, 48(5): 308-312.
[3]	Zhong Yang, He Miao, Liu Zhi, Chen Jianyu, Zhang Guangnian, Qin Long, Li Ting, Li Jianshui. Effects of Ophiopogon D combined with cyclooxygenase-2 silencing on proliferation, migration and invasion of human pancreatic cancer BxPC-3 cells [J]. Journal of International Oncology, 2021, 48(10): 583-590.
[4]	Li Keke, Kong Panpan, Yi Chao, Wang Xiyan, Yan Dong. Expression of lymphoid enhancer factor-1 in pancreatic ductal adenocarcinoma and its effect on prognosis [J]. Journal of International Oncology, 2021, 48(10): 608-613.
[5]	Chen Xiaoxu, Yu Yang, Zhang Tianxue. A prognostic risk assessment model for pancreatic cancer established based on immune-related lncRNAs [J]. Journal of International Oncology, 2020, 47(8): 472-479.
[6]	Tian Chunfang, Sha Dan. Zinc finger proteins and digestive system cancers [J]. Journal of International Oncology, 2020, 47(2): 115-118.
[7]	Ji Zhouxin, He De. Microbiota and pancreatic cancer [J]. Journal of International Oncology, 2020, 47(1): 46-50.
[8]	Li Qinghe, Liu Huichun, Zhang Jiayao, Li Wei. Study on the molecular mechanism of miR-200b-3p regulates the proliferation, invasion, migration and apoptosis of pancreatic cancer cells by down-regulating VEGFA [J]. Journal of International Oncology, 2019, 46(11): 649-656.
[9]	Li Zhi, Xu Jingkai, Zhang Bo. Mechanisms of long non-coding RNAs in tumors [J]. Journal of International Oncology, 2018, 45(4): 220-222.
[10]	Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer [J]. Journal of International Oncology, 2018, 45(3): 180-182.
[11]	Liang Biyu, He Weiming, He Xiaoyi, Ding Yuanlin, Yu Haibing. Diabetes, hypoglycemic drugs and pancreatic cancer [J]. Journal of International Oncology, 2018, 45(3): 183-186.
[12]	Chen Luojun, Li Na, Tian Jingyuan, Xu Bin, Song Qibin. Analysis of prognosis factors in nonfunctional pancreatic neuroendocrine carcinoma [J]. Journal of International Oncology, 2018, 45(12): 721-726.
[13]	WANG Yun-Liang, LI Cui. Prognostic significance of HMGA1 and HMGA2 proteins expressions in pancreatic carcinoma [J]. Journal of International Oncology, 2017, 44(5): 346-350.
[14]	HUANG Fan, JING Hong-恩. CXCL5/CXCR2 biological axis in pancreatic cancer [J]. Journal of International Oncology, 2017, 44(2): 148-150.
[15]	于兰，张小涛，李进英，王玉. Clinical application of FOLFIRINOX regimen for pancreatic cancer [J]. Journal of International Oncology, 2017, 44(11): 874-878.